TriangleNCT02837042 · OUTCOME
Progression-free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- days
- Interval / dispersion
- Inter-Quartile Range
- Time frame
- Baseline up to two years
What was measured
The duration of time from the start of treatment to the first documentation of tumor progression.
Analysis population: Since the trial stopped due to poor accrual, and more censored patients, the 95% CI for median PFS and OS could not be determined. We are reporting median values without CI.
Groups in this outcome
Pembrolizumab 200 mg
Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks. Pembrolizumab: Pembrolizumab will be administered intravenously every 3 weeks.
| Group | Source count |
|---|---|
| Pembrolizumab 200 mg | 6 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pembrolizumab 200 mg | 91 | Not reported | NA | NA | The study was ended prematurely due to poor accrual and only two patients progressed while the rest were lost to follow up. The statistical analysis will not give a reliable range except median based on two findings |
Complete source fields
- classes
- categories
- measurements
- comment
- The study was ended prematurely due to poor accrual and only two patients progressed while the rest were lost to follow up. The statistical analysis will not give a reliable range except median based on two findings
- group Id
- OG000
- lower Limit
- NA
- upper Limit
- NA
- value
- 91
- denoms
- counts
- group Id
- OG000
- value
- 6
- units
- Participants
- description
- The duration of time from the start of treatment to the first documentation of tumor progression.
- dispersion Type
- Inter-Quartile Range
- groups
- description
- Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks. Pembrolizumab: Pembrolizumab will be administered intravenously every 3 weeks.
- id
- OG000
- title
- Pembrolizumab 200 mg
- param Type
- MEDIAN
- population Description
- Since the trial stopped due to poor accrual, and more censored patients, the 95% CI for median PFS and OS could not be determined. We are reporting median values without CI.
- reporting Status
- POSTED
- time Frame
- Baseline up to two years
- title
- Progression-free Survival (PFS)
- type
- SECONDARY
- unit Of Measure
- days
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice